Cohort Description

Recruitment

As of September 2019 AOCS has recruited approximately 2,669 women with invasive or borderline ovarian cancer and 1,065 matched women with no cancer (controls). Recruitment of patients with invasive disease, either at primary diagnosis or relapse is ongoing.

We have received a total of 2,157 completed epidemiological questionnaires for eligible women with cancer and 1,064 for controls.

Extensive clinical information is collected on patients enrolled in AOCS. The following are examples of data items that can be supplied for approved project requests: Patient age; FIGO stage/sub-stage; Residual disease (nil, <1 cm, >1 cm); Type of primary treatment (surgery/drug type/neo-adjuvant); Time to relapse (or last follow-up); Time to death (or last follow-up); Details of primary chemotherapy; Details of subsequent treatment (following relapse); Best response to primary and subsequent treatment.

 

Collection of Ascites and Relapse Disease

A number of the women in AOCS will relapse and, where practical, we are collecting relapse ascites and tumour tissue (excess to diagnostic requirements) from women who present with recurrent disease. As of September 2019 we have collected over 543 relapse samples, equating to 259 patients. These samples have already been invaluable to research on acquired chemotherapy resistance.

 

Bio-Specimen Collection

The table below shows the number of women from whom we have collected particular biological specimen. These biospecimens, extracted DNA and RNA, together with associated data, are available to approved researchers. Details of how to apply are available here.

Resource	Number Available
Bloods	2304
Bloods (Controls)	924
LCLs	341
Frozen Tissue	1360
FFPE Blocks	2439
Ascites Fluid (primary or relapse)	342
TMAs	62 versions (representing ~ 1493 cases)

as of 2 September 2019